NCT02975557View on ClinicalTrials.gov

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

April 13, 2017

Study Completion Date

April 13, 2017

Conditions
Dry EyeOcular Graft vs Host DiseaseMeibomian Gland Dysfunction
Interventions
DRUG

Brimonidine 0.15%

Brimonidine 0.15% eye drops 2 times a day for 12 weeks

DRUG

Brimonidine 0.075%

Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.

DRUG

Placebo

Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.

Trial Locations (2)

60612

Illinois Eye and Ear Infirmary, University of Illinois, Chicago

Translational Clinic of Corneal Neurobiology Laboratory, Illinois Eye and Ear Infirmary, University of Illinois, Chicago

Sponsors

Collaborators (1)

Ocugen
All Listed Sponsors
collaborator

Ocugen

INDUSTRY

lead

Sandeep Jain, MD

OTHER